INT313869

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.63
First Reported 2010
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 4
Total Number 12
Disease Relevance 3.10
Pain Relevance 0.23

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

oxidoreductase activity (Pah)
Anatomy Link Frequency
lymphocyte 1
NK cells 1
T lymphocyte 1
Pah (Mus musculus)
Pain Link Frequency Relevance Heat
Calcium channel 6 98.72 Very High Very High Very High
Inflammatory mediators 3 96.40 Very High Very High Very High
beta blocker 3 93.88 High High
antagonist 3 93.76 High High
cytokine 9 5.00 Very Low Very Low Very Low
fluoxetine 9 5.00 Very Low Very Low Very Low
Inflammatory response 9 5.00 Very Low Very Low Very Low
antidepressant 9 5.00 Very Low Very Low Very Low
headache 9 5.00 Very Low Very Low Very Low
cva 6 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Pulmonary Hypertension 198 100.00 Very High Very High Very High
INFLAMMATION 12 96.40 Very High Very High Very High
Heart Rate Under Development 3 92.48 High High
Disease 51 91.56 High High
Birth Weight 63 89.52 High High
Liver Disease 3 88.56 High High
Nicotine Addiction 54 88.20 High High
Hypertension 18 83.52 Quite High
Disease Progression 6 80.40 Quite High
Dyslipidemia /

Combined Dyslipidemia

3 80.16 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
The recognition that PAH progression was characterized by vascular remodeling and an imbalance between proliferative and anti-inflammatory mediators led to the identification of the importance of endothelin, prostacyclin, and nitric oxide (NO) in disease initiation and progression (Figure 1).
Gene_expression (progression) of PAH associated with pulmonary hypertension, inflammatory mediators and disease
1) Confidence 0.63 Published 2010 Journal Drug design, development and therapy Section Body Doc Link PMC2880338 Disease Relevance 1.17 Pain Relevance 0.10
Sildenafil in other acquired PAH
Gene_expression (acquired) of PAH associated with pulmonary hypertension
2) Confidence 0.63 Published 2010 Journal Drug design, development and therapy Section Body Doc Link PMC2880338 Disease Relevance 0.69 Pain Relevance 0.05
Costs of PAH therapy
Gene_expression (therapy) of PAH associated with pulmonary hypertension
3) Confidence 0.55 Published 2010 Journal Drug design, development and therapy Section Body Doc Link PMC2880338 Disease Relevance 0.84 Pain Relevance 0.08
The results from multivariable linear regression model adjusted for year of birth and district show that total PAH exposure during the first two months of gestation was associated with increased T lymphocyte fractions CD3+ and CD4+ but not with CD8+.
Gene_expression (exposure) of PAH in T lymphocyte
4) Confidence 0.28 Published 2010 Journal Environ Health Section Body Doc Link PMC2927516 Disease Relevance 0 Pain Relevance 0
For a 100 ng/m3 increase in PAH exposure during month one was associated with a 1.1% (95% CI: 0.3, 2.0) decrease in CD19+ cells (Figure 7).
Gene_expression (exposure) of PAH
5) Confidence 0.28 Published 2010 Journal Environ Health Section Body Doc Link PMC2927516 Disease Relevance 0 Pain Relevance 0
For instance, a 100 ng/m3 incremental increase in PAH exposure during month eight was associated with reduction of CD3+ cells by 2.6% (95% CI: 1.2, 3.9) and CD4+ cells by 1.8% (95% CI: 0.6, 2.9).
Gene_expression (exposure) of PAH
6) Confidence 0.28 Published 2010 Journal Environ Health Section Body Doc Link PMC2927516 Disease Relevance 0 Pain Relevance 0
Twelve compounds in ambient air (phenanthrene, anthracene, fluoranthene, pyrene, benzo(a)anthracene, chrysene, benzo(b)fluoranthene, benzo(k)fluoranthene, benzo(a)pyrene (BaP), dibenzo(ah)anthracene, benzo(ghi)perylene, indeno(cd)pyrene) were measured individually and their sum was used as the total PAH levels for analysis.
Gene_expression (levels) of PAH
7) Confidence 0.25 Published 2010 Journal Environ Health Section Body Doc Link PMC2927516 Disease Relevance 0.07 Pain Relevance 0
Results were expressed as changes in distribution of lymphocyte subtype with a monthly average increase of 100 ng/m3 PAH exposure or a monthly average increase of 25 ?
Gene_expression (exposure) of PAH in lymphocyte
8) Confidence 0.25 Published 2010 Journal Environ Health Section Body Doc Link PMC2927516 Disease Relevance 0.25 Pain Relevance 0
The reduction in CD8+ fractions was observed only in the ninth month: PAH exposure reduced the cell by 1.0% (95% CI: 0.3, 1.6) (Figure 3).
Gene_expression (exposure) of PAH
9) Confidence 0.25 Published 2010 Journal Environ Health Section Body Doc Link PMC2927516 Disease Relevance 0 Pain Relevance 0
However, among those with greater total PAH exposure in months seven to nine, CD3+ and CD4+ cell fractions were lower.
Gene_expression (exposure) of PAH
10) Confidence 0.25 Published 2010 Journal Environ Health Section Body Doc Link PMC2927516 Disease Relevance 0 Pain Relevance 0
The percentage of NK cells was lower for those with higher PAH exposures in the first two months, no significant association with exposures from months three through six, and an increase in percentage relative to ambient PAHs measured during months seven through nine.
Gene_expression (exposures) of PAH in NK cells
11) Confidence 0.25 Published 2010 Journal Environ Health Section Body Doc Link PMC2927516 Disease Relevance 0 Pain Relevance 0
For example, there was 1.4% (95% CI: 0.1, 2.7) decrease during month one and 1.2% (95% CI: 0.1, 2.4) increase during month eight for a 100 ng/m3 increase in PAH exposure (Figure 9).
Gene_expression (exposure) of PAH
12) Confidence 0.25 Published 2010 Journal Environ Health Section Body Doc Link PMC2927516 Disease Relevance 0 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox